Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426

BACKGROUND: Currently, only a few treatment options exist for performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC), whereas the carboplatin/nab-paclitaxel (CBDCA/nab-PTX) regimen is attracting attention as a standard of care for PS 0–1 patients because of its wide suit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichikawa, Yasuko, Seki, Nobuhiko, Honda, Takeshi, Sakugawa, Makoto, Hosokawa, Shinobu, Bessho, Akihiro, Agemi, Yoko, Shimokawa, Tsuneo, Otani, Sakiko, Nakahara, Yoshiro, Naoki, Katsuhiko, Yomota, Makiko, Hosomi, Yukio, Takiguchi, Yuichi, Tokito, Takaaki, Ando, Shuji, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175006/
https://www.ncbi.nlm.nih.gov/pubmed/37180670
http://dx.doi.org/10.21037/tcr-22-2144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175006/
https://www.ncbi.nlm.nih.gov/pubmed/37180670
http://dx.doi.org/10.21037/tcr-22-2144

Ejemplares similares